A power morcellator class action represents one of the most significant medical device litigation efforts in recent history, involving thousands of women who underwent hysterectomy and fibroid removal surgeries that inadvertently spread undetected cancers throughout their bodies. The FDA estimated that approximately 1 in 350 women undergoing these minimally invasive procedures harbored unsuspected uterine cancer—a risk that manufacturers failed to adequately communicate to patients and surgeons before the devices were widely adopted.
In real terms, this meant that if a surgeon performed morcellations on 350 women believing the procedure was safe for all of them, one woman would likely have her cancer spread to her abdomen, pelvis, and surrounding tissues due to the fragmentation process itself. The power morcellator litigation primarily targeted Johnson & Johnson’s Ethicon unit and other device manufacturers, resulting in settlements ranging from $100,000 to over $1 million per plaintiff depending on age, health status, and whether cancer was detected before or after the procedure. By November 2022, when multidistrict litigation was largely concluded, these cases had reshaped how gynecological surgery is performed and exposed the gaps in how medical devices are approved and monitored for safety after they reach the market.
Table of Contents
- What Is a Power Morcellator and How Does It Spread Cancer?
- FDA Safety Warnings and the Scientific Evidence Behind the Restrictions
- The Litigation Timeline and Settlement Landscape
- Settlement Amounts and What Affects Your Eligibility
- Long-Term Health Impacts and the Physical Reality of Advanced Sarcoma
- Affected Devices and Manufacturer Responses
- How Surgery Practice Changed and the Path Forward
What Is a Power Morcellator and How Does It Spread Cancer?
A power morcellator is a surgical instrument used during minimally invasive (laparoscopic) procedures to break apart and remove fibroid tumors or the entire uterus in small pieces through tiny incisions. The device works by rapidly rotating a blade that shreds tissue into fragments, which are then suctioned out through small ports. For decades, surgeons and manufacturers promoted this approach as superior to traditional open surgery because it meant smaller incisions, less pain, faster recovery, and shorter hospital stays—benefits that were real and valuable for many patients. The critical problem emerged when an undetected malignancy was present in the uterus or surrounding tissue. When the morcellator’s spinning blade fragmented cancerous tissue, it scattered malignant cells throughout the abdominal cavity and pelvis, contaminating healthy organs and tissue planes that would have remained isolated during open surgery.
A woman who underwent morcellation for what her surgeon believed was a benign fibroid could end up with stage III or IV uterine sarcoma because the cancer that was present but undetected got mechanically dispersed. Unlike open surgery, where the intact organ (along with any undetected cancer) could be removed as a single specimen and inspected, morcellation destroyed the cancer’s contained structure. The FDA’s concern wasn’t theoretical. The agency estimated that approximately 1 in 352 women undergoing hysterectomy for fibroids harbored unsuspected uterine sarcoma (a type of uterine cancer), and 1 in 498 had unsuspected uterine leiomyosarcoma specifically. These were not rare occurrences—they were frequent enough to be a serious population-level risk that manufacturers and the FDA eventually acknowledged should have prompted different safety precautions.
FDA Safety Warnings and the Scientific Evidence Behind the Restrictions
On April 14, 2014, the FDA issued an unprecedented safety communication that fundamentally discouraged the use of power morcellators for fibroid removal. This was not a ban—the devices remained on the market—but the warning signaled that the FDA had concluded the cancer risk was significant enough that the benefit of minimally invasive surgery no longer justified that particular approach. The FDA based this decision partly on data showing the prevalence of unsuspected sarcomas and partly on a growing body of case reports from women diagnosed with advanced cancer after morcellation procedures. A key limitation of the FDA’s regulatory approach is that power morcellators were cleared for market through the 510(k) process, meaning they were approved based on “substantial equivalence” to predicate devices rather than independent clinical trials demonstrating their safety for all patient populations.
This meant that the true frequency of unsuspected cancers in the patient population undergoing these procedures wasn’t systematically tracked until cases of advanced sarcomas began appearing after surgery. The FDA gathered its safety data not from controlled studies but from adverse event reports and published case series—essentially learning about the problem after thousands of women had already been treated. The warning emphasized that if morcellation was deemed appropriate, it should only be performed in a contained environment (such as within a specimen bag) rather than open cavity morcellation. However, this “contained morcellation” recommendation created its own problems: it was technically difficult, increased procedure time, increased costs, and many surgeons lacked the training to perform it effectively. In many cases, the practical response to the FDA warning was for surgeons to abandon morcellation altogether and return to traditional open hysterectomy—a shift that meant the patients who most wanted minimally invasive surgery no longer had access to it based on a risk that applied to a subset of the population.
The Litigation Timeline and Settlement Landscape
johnson & Johnson’s ethicon unit, the manufacturer of the Gynecare Morcellex morcellator, faced the bulk of the litigation pressure. By March 2016—just two years after the FDA warning—J&J had settled approximately 70 percent of roughly 100 pending lawsuits, signaling that the company decided continued litigation was more costly and risky than paying settlements. These early settlements established a framework that other manufacturers would follow, though individual case outcomes varied significantly based on whether a woman’s cancer was detected before or after morcellation, her age at the time of surgery, her current health status, and whether she had children. The multidistrict litigation (MDL) established in federal court allowed hundreds of cases to be coordinated, sharing discovery and expert witnesses rather than each plaintiff filing independently.
This consolidation was necessary given the volume of claims but also created pressure on individual plaintiffs to accept settlement offers rather than proceeding to trial. Most women in the MDL eventually settled rather than taking cases to jury trial, meaning the full extent of their damages and the full liability of manufacturers were never tested in a public forum. By November 2022, the MDL was dissolved after settling or dismissing nearly all cases, with only two cases remaining unresolved. This marked the effective end of mass litigation over the devices, though individual suits could still theoretically be filed by women within applicable statute of limitations periods. The rapid resolution—essentially complete by 2022—reflected both the strength of the plaintiffs’ evidence and the willingness of defendants to pay substantial sums to avoid years of litigation and negative publicity.
Settlement Amounts and What Affects Your Eligibility
Individual settlements in the power morcellator class action ranged between $100,000 and $1 million, with the amount typically determined by several key factors. A woman who was in her 40s at the time of surgery, was diagnosed with advanced uterine sarcoma after morcellation, required chemotherapy and radiation, and had dependent children might receive a settlement at the higher end ($600,000 to $1 million). A woman in her 60s whose sarcoma was detected during the morcellation procedure itself and required limited additional treatment might receive $150,000 to $300,000. The settlement framework created a tradeoff between certainty and upside: accepting a settlement guaranteed a specific amount of money but precluded a jury verdict that might have been larger (or smaller).
Women who declined settlement offers and proceeded to trial faced the risk of losing entirely and receiving nothing if a jury decided the manufacturer wasn’t liable or that the link between the morcellation and their cancer wasn’t proven. In practice, few women chose this path; the economics and emotional toll of litigation made settlement the practical choice for most. Eligibility generally required proof of undergoing a morcellation procedure using a named device (typically Ethicon Gynecare Morcellex, Blue Endor MoreSolution, or Karl Storz Rotocut G1 morcellators) followed by a diagnosis of uterine sarcoma or leiomyosarcoma. Medical records documentation was critical—without surgical reports clearly stating which device was used and pathology confirming a sarcoma diagnosis, claims were difficult to substantiate.
Long-Term Health Impacts and the Physical Reality of Advanced Sarcoma
Women who had their uterine cancers inadvertently spread by morcellation often faced significantly worse prognosis and treatment outcomes compared to women whose cancers were detected before surgery. A woman with stage I sarcoma has a much higher five-year survival rate than a woman with stage III or IV sarcoma—the difference between 70-80 percent survival and 20-40 percent. Many women who underwent morcellation with undetected cancer found themselves requiring aggressive chemotherapy, radiation therapy to the abdomen and pelvis (with its own long-term side effects), possible secondary surgeries, and lifelong surveillance for recurrence. The long-term quality of life impacts extended beyond cancer treatment itself. Women who received abdominal and pelvic radiation faced increased risks of secondary cancers, bowel dysfunction, sexual dysfunction, and infertility.
Some women experienced permanent changes to their digestive and urinary systems. A 45-year-old woman diagnosed with advanced sarcoma after morcellation might face decades of living as a cancer survivor—and the settlement amounts, while substantial, had to account for these ongoing medical needs and the emotional trauma of having a preventable complication occur during a routine surgery. A significant limitation in the available data is that long-term outcomes for morcellation-complicated sarcomas haven’t been systematically compared to outcomes for women whose sarcomas were detected before surgery. This means the exact magnitude of harm attributable to morcellation versus the baseline aggressiveness of the disease isn’t fully quantified. However, the volume of litigation and settlements was driven by the reasonable inference that spreading cancer during surgery worsens outcomes compared to discovering it beforehand.
Affected Devices and Manufacturer Responses
The power morcellator lawsuits primarily involved three devices: Ethicon’s Gynecare Morcellex (the most heavily marketed), Blue Endor’s MoreSolution Tissue Morcellator, and Karl Storz’s Rotocut G1 Morcellator. Ethicon’s device represented the bulk of cases because it had the largest market share and had been used in tens of thousands of procedures before the FDA warning. Following the April 2014 FDA safety communication and the subsequent litigation, J&J withdrew its laparoscopic power morcellators from the U.S.
Market entirely. The withdrawal of these devices effectively ended the morcellation era for routine fibroid removal in the United States, though some surgeons continued using older morcellators in specific circumstances (such as contained morcellation or for specific tumor types where the risk-benefit calculation differed). The devices themselves—once considered state-of-the-art minimally invasive tools—became symbols of how thoroughly a technology can fall from favor once safety concerns become evident.
How Surgery Practice Changed and the Path Forward
The power morcellator litigation and FDA actions fundamentally reshaped gynecological surgery in the United States. Surgeons who once routinely offered morcellation to patients wanting minimally invasive fibroid removal now typically counsel patients toward open hysterectomy, laparoscopic myomectomy (fibroid removal while preserving the uterus), or robotic-assisted surgery with contained specimen extraction. For many patients, especially those in their 40s and 50s, this represented a real decrease in the availability of the least-invasive surgical option—a consequence of the power morcellator litigation that extended beyond the women who actually experienced complications.
Looking forward, the morcellator cases established a precedent for FDA and courts treating population-level risk and cancer spread during surgery with serious regulatory attention. The case demonstrated that devices can be approved and widely adopted based on technological elegance and short-term patient benefits without adequate premarket understanding of rare but serious risks—and that these risks may not be apparent until hundreds or thousands of procedures have been performed. For future devices, the morcellator litigation created pressure for more rigorous premarket analysis of how a device might perform in the subset of patients with undiagnosed diseases.
You Might Also Like
- Zetia Vytorin Cholesterol Antitrust Class Action Settlement
- Zetia Cholesterol Drug Antitrust Class Action Settlement
- Wright Hip Implant Metallosis Class Action
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: